Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
allo-APZ2-OTS in epidermolysis bullosa
NCT05838092Phase 3Active, not recruiting
- Sponsor
- RHEACELL
- Start
- Oct 2023
- Primary completion
- Aug 2025
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 3 trial of EBESANAR in epidermolysis bullosa (EB), sponsored by RHEACELL. Started Oct 2023; status: active, not recruiting.
02
Drugs
EBESANAR
03
Conditions
epidermolysis bullosa (EB)
Beyond the preview
Go deeper on NCT05838092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05838092.